Peter Thiel and other tech billionaires are publicly shielding their children from the products that made them rich Former ...

Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AMLHOUSTON, ...

Universal month-3 NGF MRD negativity (10⁻⁵) followed short-course VRd or daratumumab-based induction and single-infusion YK-hBCMA BB-002, despite high-risk biology and frailty representation. Depth of ...

A treatment regimen of penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) achieved its primary endpoint in newly diagnosed primary central nervous system lymphoma ...

The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed maintenance lenalidomide and daratumumab as well as the clinical potential of MRD in multiple myeloma.

Early intensive treatment for PsA with csDMARDs or 6 months of TNFi is superior to standard step-up care, and better outcomes ...

A >500-patient, randomized, double-blind phase 3 trial showed CT-P43 achieved PASI 75 equivalence at week 12 versus ustekinumab under standard induction and q12w maintenance dosing. Durability through ...

Description: Treatment for Headaches, Gentle Harmonic Balance Music, Sleep Induction Subliminal Message. Music to Relieve Headaches, Relaxing Music for Headaches, Digital Therapy Meditation Music, ...

The availability of TNF inhibitor biosimilars and the cost of treating ‘difficult-to-treat’ RA are making first-line TNF inhibition in early RA more attractive in the UK.

While there is no cure for ANCA-associated vasculitis (AAV), treatment is usually very effective at bringing it under control and preventing life-threatening complications. This group of rare ...

A single-arm, multicenter Dutch phase 2 study enrolled cT2–T4aN0–2M0 patients (ECOG 0–1) and used induction dual checkpoint blockade followed by mitomycin/fluoropyrimidine-based chemoradiotherapy.